D-Ribosa

D-Ribose: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Names and Classification

D-Ribose is a pentose monosaccharide — a simple, five-carbon sugar. Its molecular formula is C₅H₁₀O₅, meaning it contains five carbon atoms, ten hydrogen atoms, and five oxygen atoms. There are two enantiomeric forms of the sugar ribose: L-ribose and D-ribose. L-ribose is man-made (non-natural), but the body endogenously produces D-ribose. In chemical nomenclature, D-ribose is also known as D-(−)-ribose, reflecting its optical rotation, and bears the IUPAC name (2R,3R,4S)-2,3,4,5-tetrahydroxypentanal. D(−)Ribose is a pentose sugar that can be purchased as a crystalline product.

1.2 Natural Occurrence

D-Ribose is a naturally occurring sugar molecule found in various living organisms, including plants and animals. Ribose is present in all plant and animal cells. Small amounts of the sugar can also be found in ripe fruits and vegetables. Cells use this simple sugar to make RNA, DNA, and adenosine triphosphate (ATP), which supplies energy to cells. Ribose is also a main constituent of nucleic acids, which can be isolated from yeast or liver.

1.3 Commercial Sources and Production

D-Ribose powder can be extracted from corn syrup, a common and commercially available source, and corn-derived D-ribose is often used in the production of dietary supplements. Potato starch can also be converted by an enzymatic process into a ribose-rich ingredient. At the industrial scale, a commercially significant method involves microbial fermentation: the novel food ingredient marketed as Bioenergy Ribose™ is produced by fermentation using a transketolase-deficient strain of Bacillus subtilis. This strain's transketolase deficiency directs metabolic flux away from the pentose phosphate pathway's non-oxidative branch and towards ribose accumulation. D-Ribose can also be synthesized in the laboratory through chemical processes, involving the conversion of other sugars, such as glucose, into D-ribose through chemical reactions.

1.4 Common Forms and Preparations

D-Ribose is taken in tablets/capsules or as loose powder dissolved in water. This natural sugar is available in health stores and online in supplement form as a powder, chewable tablet, or capsule; in powder form it can be taken in water, added to other beverages such as smoothies, or mixed into kefir or yogurt. Many companies also add the supplement to energy drinks. D-ribose is additionally formulated as a component of multi-ingredient products, including combinations with creatine, coenzyme Q10, and B-vitamins.

2. Traditional and Historical Use

D-Ribose does not have a documented history of traditional or ethnobotanical use in any pre-modern medical system. Unlike many botanical dietary supplements, ribose was not isolated from a plant with a centuries-long medicinal heritage; rather, it is a molecule ubiquitous in all living matter that was first identified and characterized through the development of modern biochemistry in the late nineteenth and early twentieth centuries. The structural role of ribose as the backbone sugar of ribonucleic acid (RNA) and adenosine triphosphate (ATP) was elucidated in the mid-twentieth century as part of the broader revolution in molecular biology.

Scientific interest in D-ribose as a potential therapeutic or supplemental agent originated in the late 1970s and 1980s, when researchers, notably Heinz-Gerd Zimmer and collaborators in Germany, began publishing animal-model studies demonstrating that exogenously supplied ribose could accelerate the restoration of myocardial ATP levels following ischemic injury. Researchers demonstrated that the depletion in myocardial ATP levels following ischemia can last for a considerable time period due to slow adenine nucleotide synthesis, and that an extended time period was required for recovery of depressed myocardial energy levels as well as improvement in mechanical function following ischemia. It was this body of preclinical animal work — not a traditional use heritage — that set the stage for subsequent clinical investigation. Over decades, researchers explored the use of various metabolites to replenish deficient cellular energy levels following induced ischemia with mixed results; however, D-ribose demonstrated significant enhancing abilities in replenishing deficient cellular energy levels following myocardial ischemia, as well as improving depressed function in numerous animal investigations.

Use of D-ribose as a dietary supplement sold to consumers became commercially prominent in the late 1990s and early 2000s, following publication of the first human clinical studies and the filing of multiple patents covering ribose's use in cardiovascular disease and sports nutrition. In sporting circles, D-ribose came to be used as a dietary supplement to more quickly reproduce ATP consumed during muscle activity and to therefore reduce the regeneration phase between training units.

3. Key Constituents and Mechanisms of Action

3.1 The Pentose Phosphate Pathway and ATP Synthesis

The primary basis for D-ribose's proposed therapeutic effects lies in its central role in cellular energy metabolism. Ribose is a naturally occurring carbohydrate that plays a crucial role in the production of ATP, the primary energy source for cells in the human body. Within cells, exogenously supplied D-ribose can undergo phosphorylation to yield ribose-5-phosphate (R-5-P), which serves a dual purpose: it not only contributes to ATP production through the nonoxidative phase of the pentose phosphate pathway (PPP) but also participates in nucleotide synthesis.

The body normally synthesizes ribose-5-phosphate from glucose via the pentose phosphate pathway (PPP). The PPP generates nicotinamide adenine dinucleotide phosphate (NADPH), pentoses, and ribose-5-phosphate; however, this is a slow process that requires the enzyme glucose-6-phosphate dehydrogenase (G-6-PDH), which is often in short supply within cells and can have limited expression in myocardial cells with cardiac disease, leading to significant delay in the production of ribose. Supplemental D-ribose bypasses the upper part of the pentose pathway and is an alternative source for 5-phospho-D-ribose 1-pyrophosphate (PRPP).

Ribose-5-phosphate is not used directly for either purine or pyrimidine synthesis; rather, it is used to synthesize the "active pentose" — 5-phosphoribosyl-1-pyrophosphate (PRPP) — through the enzyme PRPP synthase. PRPP is the activated five-carbon sugar used for nucleotide synthesis and provides both the sugar and phosphate group to nucleotides. PRPP is utilized in the biosynthesis of purine and pyrimidine nucleotides, the amino acids histidine and tryptophan, and the cofactors NAD and related metabolites. Through this route, supplemental ribose supports the de novo synthesis of adenine nucleotides, including AMP, ADP, and ultimately ATP.

Supplemental ribose enters the pentose phosphate pathway, bypassing the rate-limiting steps, leading to the formation of adenine nucleotides. Supplemental D-ribose has been shown to improve cellular processes when there is mitochondrial dysfunction; when individuals take supplemental D-ribose, it can bypass part of the pentose pathway to produce D-ribose-5-phosphate for the production of energy.

3.2 Implications for Ischemic and Metabolically Stressed Tissue

Myocardial ischemia depletes ATP levels, which can affect intracellular reactions and the cells' function; if ischemia is severe enough, cell viability is jeopardized. Researchers have also demonstrated that this depletion in myocardial ATP levels following ischemia can last for a considerable time period due to slow adenine nucleotide synthesis. This suggests that D-ribose may effectively increase ATP synthesis and thus its levels, reducing the damage caused by cardiac ischemia and tissue hypoxia. However, D-ribose is not the preferred substrate for cardiac energy production and cannot provide comparable oxidative energy compared with glucose or pyruvate.

Both pathways can supply ATP for cells to facilitate their growth. However, when excessive D-ribose is deposited in the cell, it can also initiate rapid nonenzymatic glycation reactions (advanced glycation end-products, or AGEs), which can cause damage to the cells. The toxicity mechanism of D-ribose is primarily associated with AGEs, a diverse and highly reactive group of compounds; the interaction of AGEs with their primary cellular receptor, RAGE, activates multiple signalling pathways, including MAPK/ERK, TGF-β, JNK, and NF-κB, culminating in escalated oxidative stress and inflammation. These processes are linked to various maladies such as diabetes, kidney disease, Alzheimer's disease, and cataracts. This AGE-formation pathway represents a potential adverse mechanism that is distinct from its energy-metabolic benefits and is a focus of ongoing research.

3.3 Blood Glucose Regulation

D-Ribose is metabolized completely differently compared to sucrose; its intake does not cause a rise but rather a reduction of the blood sugar level. Ribose therefore has a negative glycemic index because the blood sugar level is lowered after the consumption of ribose. Bolus oral D-ribose can induce a dose-dependent transient hypoglycemia that is preceded by a transient spike in insulin levels, which can result in symptomatic hypoglycemia in subjects whose blood glucose levels fall sufficiently far.

3.4 NAD⁺ Metabolism

More recent research has examined D-ribose's role in supporting the NAD⁺ metabolome. Multiple experiments have demonstrated that nicotinamide riboside (NR) degrades very quickly into nicotinamide and ribose, especially when ingested orally. Therefore, reported benefits of NR could be attributable to circulating nicotinamide or nicotinamide and ribose. This observation has prompted investigation into combinations of nicotinamide and D-ribose as direct NAD⁺ precursors.

4. Scientific Evidence by Area of Use

4.1 Cardiovascular Disease: Congestive Heart Failure and Ischemia

This is the area where D-ribose has the most substantive, though still limited, body of human clinical evidence.

Animal/preclinical evidence: D-Ribose has been shown in animal models to improve cardiac energy metabolism and function following ischaemia. Supplemental D-ribose has been investigated in animal models to enhance myocardial metabolism and performance following myocardial ischemia.

Key clinical trial — Omran et al. (2003): A prospective, double-blind, randomized, crossover design study assessed the effect of oral D-ribose supplementation on cardiac hemodynamics and quality of life in 15 patients with chronic coronary artery disease and congestive heart failure (CHF). The study consisted of two treatment periods of 3 weeks, during which either oral D-ribose or placebo was administered followed by a 1-week washout period. Assessment of myocardial functional parameters by echocardiography, quality of life using the SF-36 questionnaire, and functional capacity using cycle ergometer testing was performed. The administration of D-ribose resulted in an enhancement of atrial contribution to left ventricular filling, a smaller left atrial dimension, and a shortened E-wave deceleration by echocardiography. D-ribose also demonstrated a significant improvement of patients' quality of life. Placebo did not result in any significant echocardiographic changes or improvement in quality of life. This feasibility study revealed beneficial effects of D-ribose in improving diastolic functional parameters and enhancing quality of life. This was a small feasibility study (n=15) and should be interpreted with appropriate caution.

Summary of clinical evidence: Clinical trials have shown that ribose supplementation improves ischemic threshold and enhances diastolic function in congestive heart failure. Although certain limitations were found in some of the studies due to sample size, the overall trend of using D-ribose supplementation for heart failure with preserved ejection fraction (HFpEF) was positive. D-ribose has been shown in animal and human studies to increase myocardial ATP production and improve cardiac function; in a few clinical trials, oral D-ribose supplementation enhanced cardiac hemodynamics, ejection fraction, and quality of life in patients with heart failure. Data are described as compelling, but preliminary, to suggest that D-ribose may be of benefit in CHF.

Evidence strength assessment: The human evidence is preliminary. Clinical trials to date have been small (often fewer than 20 subjects), short in duration, and some lack rigorous placebo controls. Some studies suggest that ribose supplementation may help restore ATP levels in the heart more quickly after oxygen deprivation, potentially benefiting individuals with conditions such as angina and congestive heart failure. However, evidence supporting its effectiveness in these areas remains preliminary and warrants further investigation.

4.2 Angina Pectoris

Individuals with sufficiently severe coronary artery disease suffer reduced blood flow to the heart (ischemia) with exercise and experience angina pain. One small study examined whether giving ribose can improve exercise tolerance for people with angina. During treadmill exercise, ribose supplementation allowed patients to exercise for a significantly longer time before developing ST changes or the occurrence of moderate angina. However, this evidence comes from a small feasibility trial, and angina management with D-ribose is listed as a "proposed" rather than established use in the published literature.

4.3 Exercise Performance and Athletic Recovery

D-Ribose has been marketed prominently to athletes and fitness enthusiasts based on the theoretical rationale that it could accelerate ATP resynthesis following intense exercise. The clinical evidence, however, has been largely negative for healthy athletes.

Despite its popularity as a sports supplement, research indicates that ribose may not enhance athletic performance, especially in high-intensity exercises, as multiple studies have shown no significant benefits compared to placebo. Some animal studies seem to show that skeletal muscle, like heart muscle, replenishes ATP more quickly when ribose is added to the blood, which in theory could lead to enhanced performance in high-intensity anaerobic exercise such as sprinting. However, six small double-blind, placebo-controlled trials in humans failed to find any benefit. In one of these studies, dextrose (a form of ordinary sugar) proved effective, while ribose did not.

One study that provided modest evidence for ribose in a recreational bodybuilder population found: the ribose-supplemented group experienced a significant pretreatment-to-posttreatment increase in total work performed, whereas the placebo group did not change significantly (a 19.6% increase in the ribose group, P = 0.028). However, this study used a dose of 10 g/day for 4 weeks in male bodybuilders and has not been consistently replicated.

A 2017 study reported some positive findings in untrained individuals: D-ribose ingestion led to a significant (p=0.04) improvement in relative mean power over dextrose.

Initial research on ribose supplementation focused on enhancing athletic performance, and current clinical evidence remains inconclusive. Overall, scientific findings for ribose's use by novice and experienced athletes to enhance performance do not support its use.

4.4 Fibromyalgia and Chronic Fatigue Syndrome

D-Ribose has been studied specifically in fibromyalgia (FMS) and chronic fatigue syndrome (CFS), two conditions hypothesized to involve impaired cellular energy metabolism.

Pilot study — Teitelbaum et al. (2006): As D-ribose had been shown to increase cellular energy synthesis in heart and skeletal muscle, this open-label, uncontrolled pilot study evaluated whether D-ribose could improve symptoms in fibromyalgia and/or chronic fatigue syndrome patients. Forty-one patients with a diagnosis of FMS and/or CFS were given D-ribose at a dose of 5 g three times daily (t.i.d.) for a total of 280 g. All patients completed questionnaires containing visual analog scales and a global assessment pre- and post-D-ribose administration. D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy, sleep, mental clarity, pain intensity, and well-being, as well as an improvement in patients' global assessment. Approximately 66% of patients experienced significant improvement while on D-ribose, with an average increase in energy on the VAS of 45% and an average improvement in overall well-being of 30% (p < 0.0001).

Multicenter open-label study — Teitelbaum et al. (2012): A follow-up study expanded the evidence base. An open-label, unblinded study in which 53 US clinics enrolled 257 patients who had been given a diagnosis of CFS/FMS by a health practitioner; all subjects were given D-ribose (Corvalen) 5 g three times daily for 3 weeks. D-ribose treatment led to both statistically (p<0.0001) and clinically highly important average improvements in all categories. Improvement began in the first week of treatment and continued to increase at the end of the 3 weeks. The D-ribose was well tolerated.

Evidence strength assessment: Both of these studies were open-label and uncontrolled, which represents a significant methodological limitation. The absence of a placebo group means that these positive findings cannot exclude placebo response and expectation bias. These results should be characterized as preliminary and hypothesis-generating. No rigorous, placebo-controlled, double-blind RCT has been completed and published for D-ribose in FMS or CFS as of the available literature.

4.5 Myoadenylate Deaminase Deficiency (MADD) and McArdle's Disease

Myoadenylate deaminase (MAD) is the rate-limiting enzyme in the purine nucleotide cycle, biochemically linked to glycolysis and the citric acid cycle, providing energy during intense muscular activity. In muscle fibers, it operates at considerably higher activity levels than in other organs; deficiency of myoadenylate deaminase appears to be one of the most frequent enzyme defects in muscle. The primary defect may occur as an isolated entity, and it is the primary, unassociated MAD deficiency that has recently become amenable to successful treatment with D-ribose in high doses. This evidence, however, is largely based on small case series and early clinical reports.

Regarding McArdle's disease (glycogen storage disease type V), the literature contains a published case report of successful symptomatic therapy by high-dose oral administration of ribose (Wagner and Zöllner, 1991, Klin Wochenschr). However, small double-blind studies have failed to find ribose effective for McArdle's disease. The EBSCO evidence database accordingly classifies McArdle's disease as a "probably not effective" use for D-ribose.

4.6 NAD⁺ Metabolome and Related Applications

A pilot randomized, triple-blind, placebo-controlled, crossover study investigated a combination product (RiaGev) containing nicotinamide and D-ribose: this study assessed the efficacy and safety of nicotinamide combined with D-ribose for NAD metabolome enhancement in healthy middle-aged adults. Supplementing with 1,520 mg RiaGev twice daily for 7 days significantly increased the NAD⁺ metabolome in blood, especially NADP⁺ by 27% compared to the placebo group (p = 0.033). Increases in glutathione and high-energy phosphates were also observed in the blood, and seven-day supplementation significantly reduced overall blood glucose without significant changes in insulin secretion, suggesting improved insulin sensitivity and glucose tolerance. This study was small and short in duration; its results relate to a combination product and cannot be attributed to D-ribose alone.

4.7 Duchenne Muscular Dystrophy

D-Ribose is classified in the published evidence literature as "probably not effective" for Duchenne muscular dystrophy. A preclinical investigation published in PLoS One (2013) found that daily supplementation of D-ribose showed no therapeutic benefits in a mouse model of inflammatory myositis, reinforcing the lack of evidence for muscular dystrophy conditions.

5. Body Systems and Health Areas

D-Ribose intersects with multiple physiological systems, primarily through its foundational role in cellular bioenergetics:

• Cardiovascular system: Ribose can aid the recovery of ATP levels and hence diastolic function; clinical trials have shown that ribose supplementation improves ischemic threshold and enhances diastolic function in congestive heart failure.
• Skeletal muscle / musculoskeletal system: Ribose, a naturally occurring pentose sugar, has been shown to enhance the recovery of myocardial or skeletal muscle ATP and total adenine nucleotide (TAN) levels following ischemia or high-intensity exercise.
• Mitochondrial function: Without sufficient energy, cells cannot maintain integrity and function. Supplemental D-ribose has been shown to improve cellular processes when there is mitochondrial dysfunction.
• Nucleic acid and coenzyme biosynthesis: Ribose-5-phosphate and its derivatives serve as precursors to many biomolecules, including DNA, RNA, ATP, coenzyme A, and FAD (flavin adenine dinucleotide).
• Blood glucose regulation: D-Ribose has a documented hypoglycemic effect distinct from that of common dietary sugars. D-Ribose can cause a drop in blood glucose levels; hypoglycemia is usually mild or asymptomatic and transient.
• NAD⁺ / redox metabolism: Via its role as a precursor of PRPP, D-ribose contributes to the biosynthesis of NAD⁺, NADH, and related coenzymes that are central to cellular redox balance.
• Neuroenerge­tics and cognitive function: Proposed as an area of interest based on cellular energy considerations, but human evidence is absent as of current literature.

6. Dosage Forms and Dosages Reported in Studies

D-Ribose is not classified as an essential nutrient, and there is no established recommended dietary allowance (RDA) or adequate intake (AI) level. Ribose is not an essential nutrient, and typical dietary sources do not provide sufficient amounts for therapeutic purposes.

The following dosages have been used in published human studies and authoritative review documents:

• Congestive heart failure (Omran et al., 2003 clinical trial): Oral D-ribose was administered for two 3-week periods in a crossover design; the specific per-dose amount in this 15-patient study was not specified in the available abstract detail but was given as an oral supplement.
• Fibromyalgia/CFS pilot study (Teitelbaum et al., 2006): Forty-one patients were given D-ribose at a dose of 5 g three times daily (t.i.d.) for a total of 280 g.
• Fibromyalgia/CFS multicenter study (Teitelbaum et al., 2012): All subjects were given D-ribose (Corvalen) 5 g three times daily for 3 weeks.
• Hematological safety study (Seifert et al., 2008): Nineteen subjects ingested 20 grams per day (10 grams, twice a day) of ribose with serial measurements at Days 0, 7, and 14.
• Bodybuilder performance trial (Van Gammeren et al., 2002): Subjects were randomized to a ribose-supplemented group (10 g/d in powder formulation) or a placebo group (dextrose) for 4 weeks.
• Patent-filed dosing range: When D(−)ribose is used as ribose source, per daily dose approximately 0.5–40 g should be included, in particular 1–15 g, and most preferably 2–10 g.
• Examine.com reported range: 3 to 60 grams per day, often divided into 3 to 4 doses throughout the day.
• EFSA-defined NOAEL and acceptable intake: The EFSA Panel derived a No Observed Adverse Effect Level (NOAEL) of 3.6 g/kg body weight per day from a subchronic toxicity study in rats. EFSA concluded that D-ribose is safe for the general population at intake levels up to 36 mg/kg body weight per day.

7. Safety Considerations and Interactions

7.1 General Tolerability

No significant toxic changes over the 14-day assessment period occurred in complete blood count, albumin, alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase. However, D-ribose did produce an asymptomatic, mild hypoglycemia of short duration. Uric acid levels increased at Day 7, but decreased to baseline values by Day 14. D-ribose consumption for 14 days appears not to produce significant toxic changes in both hematological and biochemical parameters in healthy human volunteers.

Several studies have indicated that administration of certain concentrations of D-ribose in various animal models is healthy and does not cause any adverse effects regarding behavior, hematology, biochemistry, histology, or general pathology.

7.2 Hypoglycemia

The most well-characterized and clinically significant adverse effect is transient hypoglycemia. From human studies indicating a potential decrease in glucose levels and/or the occurrence of transient symptomatic hypoglycemia at intakes of 10 g of D-ribose, the EFSA Panel defined 70 mg/kg body weight per day as the NOAEL with respect to hypoglycemia applicable for adults. Bolus oral D-ribose can induce a dose-dependent transient hypoglycemia preceded by a transient spike in insulin levels, which can result in symptomatic hypoglycemia in subjects whose blood glucose levels fall sufficiently far. This transient hypoglycemia is described as the dose-limiting side effect of D-ribose treatment, although it is reportedly readily overcome by drinking a glass of fruit juice.

7.3 Gastrointestinal Effects

Taking more than 20 g of D-ribose supplements may cause side effects such as diarrhea, nausea, heartburn, and headache. Oral administration of D-ribose to healthy people was tolerable, with instances of diarrhea occurring at doses higher than 200 mg/kg/hour.

7.4 Uric Acid

A mild state of hypoglycemia and hyperuricemia can be observed after oral consumption of D-ribose. The transient elevation in uric acid is consistent with increased purine nucleotide catabolism, as ribose drives adenine nucleotide synthesis whose degradation yields uric acid. As noted in the Seifert et al. 14-day study, uric acid levels returned to baseline by Day 14.

7.5 Advanced Glycation End-Products (AGEs)

When excessive D-ribose is deposited in the cell, it can initiate rapid nonenzymatic glycation reactions forming AGEs, which can cause damage to cells. D-Ribose is a more reactive glycating agent than glucose in vitro, and research has examined potential links between endogenous D-ribose dysmetabolism and complications associated with diabetes mellitus. Recent clinical studies have suggested a potential link between D-ribose metabolic disturbances and type 2 diabetes mellitus along with its associated complications; certain in vitro experiments have also indicated that exogenous D-ribose exposure could trigger apoptosis in specific cell lines. Further research is necessary to determine the optimal dose of D-ribose supplementation for beneficial effects and to identify any potentially harmful thresholds.

7.6 Diabetes and Blood Glucose Management

D-Ribose may not be safe for people with diabetes. If you have diabetes, you should avoid the supplement. It remains unclear whether the sugar may complicate diabetes and raise HbA1c. With diabetes medication, ribose may also lower blood sugar (hypoglycemia). In the Omran et al. clinical trial, diabetes mellitus was an explicit exclusion criterion.

7.7 Special Populations

Supplementation with ribose should be avoided during pregnancy and breastfeeding. For children, EFSA acknowledges the lack of human data directly relevant for this population group.

7.8 Regulatory Status

In the European Union, Commission Implementing Regulation (EU) 2019/506 of 26 March 2019 authorised the placing on the market of D-ribose as a novel food under Regulation (EU) 2015/2283. The EFSA Panel concluded that D-ribose is safe under the new proposed conditions of use. However, if used in conjunction with food supplements containing D-ribose, the Panel noted that the acceptable level of intake (36 mg/kg body weight per day) may be exceeded. In the United States, D-ribose is marketed as a dietary supplement under provisions of the Dietary Supplement Health and Education Act (DSHEA); it is not FDA-approved as a drug for any indication.

7.9 Long-Term Safety Data

Published studies on D-ribose have mainly centered on acute, short-term investigations, ranging from hours to a few days. Long-term controlled safety trials in humans are lacking, and this represents a fundamental gap in the evidence base.

References

• Mahoney DE, Hiebert JB, Thimmesch A, et al. "Understanding D-Ribose and Mitochondrial Function." Advances in Bioscience and Clinical Medicine, 2018. PubMed PMID 29780691.
• Wagner S, Herrick J, Shecterle LM, St Cyr JA. "D-ribose aids congestive heart failure patients." Progress in Cardiovascular Nursing, 2009. PMC2716264.
• Omran H, Illien S, MacCarter D, St Cyr J, Lüderitz B. "D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study." European Journal of Heart Failure, 2003. PMID 14607200.
• Li S, et al. "D-ribose: Potential clinical applications in congestive heart failure and diabetes, and its complications (Review)." Experimental and Therapeutic Medicine, 2021. PMC8005739.
• Shecterle LM, Terry KR, St Cyr JA. "Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease." Cureus, 2018. PMC5943027.
• Krueger DA, et al. "Mitochondrial bioenergetics and D-ribose in HFpEF: a brief narrative review." Annals of Translational Medicine, 2021.
• Teitelbaum JE, Johnson C, St Cyr J. "The Use of D-Ribose in Chronic Fatigue Syndrome and Fibromyalgia: A Pilot Study." Journal of Alternative and Complementary Medicine, 2006.
• Teitelbaum J, Jandrain J, McGrew R. "Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose – An Open-label, Multicenter Study." The Open Pain Journal, 2012.
• Seifert J, Frelich A, Shecterle L, St Cyr J. "Assessment of Hematological and Biochemical parameters with extended D-Ribose ingestion." Journal of the International Society of Sports Nutrition, 2008. PMC2569905.
• Dolopikou CF, et al. "A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD+ Metabolome in Healthy Middle-Aged Adults." Nutrients, 2022. PMC9183138.
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). "Safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283." EFSA Journal, 2018. PMC7009719.
• EFSA NDA Panel. "Statement on the safety of d‐ribose." EFSA Journal, 2020. PMC7009567.
• EFSA. "Safety of d‐ribose as a novel food pursuant to Regulation (EU) 2015/2283." EFSA Journal, 2018. DOI: 10.2903/j.efsa.2018.5265.
• Xu J, et al. "D-ribose metabolic disorder and diabetes mellitus." Frontiers in Endocrinology, 2024. PMC10822815.
• EBSCO Research Starters. "Ribose as a therapeutic supplement." Health and Medicine.
• Examine.com. "D-Ribose: Benefits, Dosage, and Side Effects." (Updated 2026).
• Shecterle LM, St Cyr JA. "The patented uses of D-ribose in cardiovascular diseases." Recent Patents on Cardiovascular Drug Discovery, 2010. PMID 20236088.
• Goebel HH, Bardosi A. "Myoadenylate deaminase deficiency." Klinische Wochenschrift, 1987. PMID 3323644.
• Van Gammeren D, Falk D, Antonio J. "The effects of four weeks of ribose supplementation on body composition and exercise performance in healthy, young, male recreational bodybuilders: a double-blind, placebo-controlled trial." Current Therapeutic Research, 2002.
• European Commission. "Union List of Novel Foods." Commission Implementing Regulation (EU) 2019/506 authorising D-ribose as a novel food.
• Hove-Jensen B, et al. "Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance." Microbiology and Molecular Biology Reviews, 2017.